Novartis Investor Presentation
New Novartis: Our strategy
Our focus
Our priorities
Improved financials
Launch excellence
High-value innovation
> Operational excellence
Strengthen foundations
Conclusion
Abbreviations
Strengthening integration within R&D to accelerate
key early programs
Selected assets with integrated plans
MBL949 (Obesity related diseases)
TIN816 (S-AKI) ATP Modulator1
XXB750 (Cardiovascular diseases)
lanalumab (LN) BAFF-R inhibitor
MAS825 (Hidradenitis Suppurativa)
BLZ945 (Amyotrophic lateral sclerosis) CSF-1R inhibitor
JDQ443 (NSCLC) KRAS inhibitor
177Lu NeoB (Solid Tumors) Radioligand therapy
MGY825 (NSCLC)
Phase 1
Phase 2
Phase 3
4. Operational excellence
Cardiovascular
Immunology
Neuroscience
Solid Tumors
24
24
Note: Bars in Gantt chart indicate current phase of development 1. Phase 2 initiating
Novartis Investor Presentation | September 22, 2022
&
NOVARTIS | Reimagining MedicineView entire presentation